1. Home
  2. XOS vs BYSI Comparison

XOS vs BYSI Comparison

Compare XOS & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xos Inc.

XOS

Xos Inc.

HOLD

Current Price

$2.09

Market Cap

37.2M

ML Signal

HOLD

Logo BeyondSpring Inc.

BYSI

BeyondSpring Inc.

HOLD

Current Price

$0.83

Market Cap

35.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XOS
BYSI
Founded
2016
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Construction/Ag Equipment/Trucks
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
37.2M
35.8M
IPO Year
2020
2016

Fundamental Metrics

Financial Performance
Metric
XOS
BYSI
Price
$2.09
$0.83
Analyst Decision
Buy
Analyst Count
1
0
Target Price
$7.00
N/A
AVG Volume (30 Days)
188.0K
1.9M
Earning Date
05-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
59.49
N/A
EPS
N/A
N/A
Revenue
$45,992,000.00
N/A
Revenue This Year
$29.02
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.60
$0.73
52 Week High
$8.27
$2.44

Technical Indicators

Market Signals
Indicator
XOS
BYSI
Relative Strength Index (RSI) 41.34 35.32
Support Level $2.12 N/A
Resistance Level $2.15 $1.84
Average True Range (ATR) 0.21 0.11
MACD 0.03 -0.00
Stochastic Oscillator 22.69 18.92

Price Performance

Historical Comparison
XOS
BYSI

About XOS Xos Inc.

Xos Inc is a fleet electrification solutions provider committed to the decarbonization of commercial transportation. Xos designs and manufactures Class 5 through 8 battery-electric commercial vehicles that travel on last-mile, back-to-base routes of up to 200 miles per day. Xos also offers charging infrastructure products and services through Xos Energy Solutions to support electric vehicle fleets. Its products include Stepvan, MDXT, HDXT, Xosphere, and Xos Energy Solutions.

About BYSI BeyondSpring Inc.

BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.

Share on Social Networks: